IQVIA Holdings Inc. (IQV)
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IQVIA (IQV) Reliance on International Sales: What Investors Need to Know
Explore IQVIA's (IQV) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
IQVIA: Q2 Earnings Exceeded My Expectations
IQVIA Holdings Inc.'s Q1 results highlighted strong profitability, robust TAS growth, and a healthy backlog, reaffirming its leadership in healthcare data and analytics. Despite sector headwinds, I remained bullish on IQVIA and expected Q2 to meet or beat estimates, viewing analyst forecasts as a conservative floor. The company did not disappoint. Key risks include delayed clinical trials, shrinking CSMS segment, regulatory challenges, and high debt, but these do not shake my conviction.
IQVIA Holdings Inc. (IQV) Q2 2025 Earnings Call Transcript
IQVIA Holdings Inc. (NYSE:IQV ) Q2 2025 Earnings Conference Call July 22, 2025 9:00 AM ET Company Participants Ari Bousbib - CEO & Chairman Kerri Joseph - Corporate Participant SVP of Investment Relation & Treasury - Corporate Participant Ronald E. Bruehlman - Executive VP & CFO Conference Call Participants Ann Kathleen Hynes - Mizuho Securities USA LLC, Research Division Christine Rains - William Blair & Company L.L.C.
IQVIA Earnings & Revenues Beat Estimates in Q2, Rise Y/Y
IQV tops second-quarter 2025 estimates, with earnings up 6.4% and revenue rising 5.5%. It cuts the 2025 EBITDA guidance.
Top Stock Movers Now: GM, Lockheed Martin, IQVIA, DR Horton, and More
Major U.S. equities indexes were mixed at midday Tuesday as investors digested the latest corporate earnings. The Dow was higher, but the S&P 500 and Nasdaq lost ground.
IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.76 per share. This compares to earnings of $2.64 per share a year ago.
Countdown to IQVIA (IQV) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Get a deeper insight into the potential performance of IQVIA (IQV) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
IQVIA Gears Up to Report Q2 Earnings: What's in Store for the Stock?
IQV is set to report Q2 results on July 22, with both earnings and revenues expected to rise on strong demand across segments.
IQVIA: Competition Is Creating More Challenges Over The Long Haul
I rate IQVIA as a hold due to long-term competitive threats, particularly from one player, and concerns about capital allocation and high debt. IQVIA's business model is solid, but declining gross margins, low ROIC, and slow innovation raise concerns about its ability to sustain long-term value. The competitor's more innovative, integrated ecosystem and better capital discipline position it to capture market share from IQVIA, especially among small biotechs and large pharma.
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why IQVIA Holdings (IQV) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
